CD4 and neoplasm: Meanwhile, the RBC‐Nanovaccines plus anti‐PD‐1 remarkably enhance the repertoires of IFN‐γ+CD4+ T cells and IFN‐γ+CD8+ T cells (Fig 5I and J, and Appendix Fig S23), thus potentiating the adaptive immune response for tumor control (Zhu et al, 2017; Zhao et al, 2021).